Under Sec. 741 of Division A(p.120), the U.S. Senate Committee on Appropriations has requested for the U.S. Federal Drug Administration (FDA) to allocate funds and resources toward the establishment of a regulatory framework for all cannabis derivatives, including cannabidiol (CBD), reported hempgrower.com
The “Cannabis and Cannabis Derivatives” section of the appropriations package states that within 90 days of enactment of the Act, the FDA shall issue a policy of enforcement discretion with regard to certain products containing CBD. “Such enforcement discretion shall be in effect until the FDA establishes a process for stakeholders to notify the FDA of use of CBD in products that include safety studies for intended use per product and makes a determination about such product.”
In addition, the Committee requested that the FDA consider moving forward with research regarding CBD and encourages the agency to partner with academic institutions to expand sampling studies of CBD products on the market.
